By DAVE TEMPLE
Director of Marketing and Corporate Communications

WARSAW — Nextremity Solutions, Inc., a pure-play foot and ankle company located in Warsaw, recently signed an exclusive agreement with California-based biotechnology company, Molecular Matrix Inc.

The agreement will give Nextremity Solutions worldwide exclusive rights for use of Molecular Matrix’s GroCell-3D technology, as well as any new musculoskeletal technologies developed by Molecular Matrix for use below the knee.

GroCell-3D is an innovative technology for growing mammalian cells and tissues on a three dimensional scaffold. The GroCell-3D scaffold has been shown to support the growth of bone, cartilage, heart, nerves, liver and stem cells, among others.

GroCell-3D is a three-dimensional cell scaffold that is safe, highly porous, biocompatible and biodegradable. Cells cultivated using the GroCell-3D scaffold have shown exceptional compatibility and growth.

The primary focus in the utilization of the scaffolds unique properties is to develop a superior, more cost-effective bone-void filler.

Molecular Matrix founder and inventor of GroCell-3D technology, Charles Lee, Ph.D., said, “As an inventor, I am intrigued to see how this technology is able to be used in real-world situations. Through this partnership, we are able to combine Molecular Matrix’s expertise in biotechnology with Nextremity’s expertise and worldwide surgeon relationships in the foot and ankle market to develop innovative treatment options that will help patients.”

“When I first heard about this technology I knew Nextremity Solutions needed to find a way to work with Molecular Matrix,”Nick Deeter, CEO and chairman of Nextremity Solutions Inc., said. “When you really think about all of the ways this technology could be used in the treatment of foot and ankle degenerative diseases and deformities, you realize that this industry is about to change. We are privileged to partner with the amazing and innovative team at Molecular Matrix,”

Deeter went on to say, “We are so excited about what MMI can do in the musculoskeletal area throughout the human body, that Nextremity has invested in MMI and our CFO, Frank Patton, will be joining their board of directors.”

Nextremity Solutions is expected to launch this technology as part of its product portfolio in 2016.

For further information, visit www.nextremitysolutions.com.